Repository Corticotropin Injection as Therapy for Rheumatoid Arthritis
In this podcast, Dhiman Basu, MD, highlights current treatment options for patients with rheumatoid arthritis (RA), findings from a phase 4 clinical trial that assessed the safety and efficacy of repository corticotropin injection among patients with refractory disease, and more.
- Fleischmann R, Furst D, Liu J, Zhu J, Connolly-Strong E, Brasington R. A multicenter study assessing the efficacy and safety of repository corticotropin injection in patients with rheumatoid arthritis: interim data from the open-label treatment period. Paper presented at: EULAR 2019; June 12-15, 2019; Madrid, Spain. https://ard.bmj.com/content/78/Suppl_2/359.1
Dhiman Basu, MD, is a rheumatologist at Heritage Rheumatology and Arthritis Care in Colleyville, Texas.
Financial Disclosures: Dr Basu has served as a paid advisory board member to AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Exagen, Horizon, Mallinckrodt Pharmaceuticals, Novartis, and UCB. Dr Basu has received speaker honoraria from AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Exagen, GlaxoSmithKline, Horizon, Novartis, Pfizer, and Sanofi Genzyme. Dr Basu has owned stock in JPMorgan Chase & Co. and Pfizer.
For more content on rheumatoid arthritis, visit our Excellence Forum.